Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

How do I: Evaluate the safety and legitimacy of unproven cellular therapies?

  • Indira Guleria
  • , Maria de Los Angeles Muñiz
  • , Matthew Wilgo
  • , Asawari Bapat
  • , Wanxing Cui
  • , Yen Michael Sheng Hsu
  • , Madhan Jeyaraman
  • , Sathish Muthu
  • , Federico Rodriguez
  • , Andrew Fesnak
  • , Christina Celluzzi
  • , Deborah Sesok-Pizzini
  • , Ronit Reich-Slotky
  • , Thomas Spitzer
  • Brigham and Women's Hospital
  • Harvard University
  • Cornell University
  • New England Cryogenic Center. Inc.
  • Infohealth FZE
  • MedStar Georgetown University Hospital
  • University of Pittsburgh
  • Sri Lalithambigai Medical College and Hospital
  • Sharda University
  • Government Medical College and Hospital
  • University of Florida
  • University of Pennsylvania
  • Association for the Advancement of Blood and Biotherapies
  • Rutgers - The State University of New Jersey, Newark
  • Massachusetts General Hospital

Producción científicarevisión exhaustiva

9 Citas (Scopus)

Resumen

Background: Unproven cellular therapies are being offered to patients for a variety of conditions and diseases for which other treatments have failed. The use of untested cellular therapies is a worldwide problem. Practitioners (e.g., physicians, scientists, QA/QI facility managers, and policy advocates) are perhaps unaware of the risks involved with such therapies. Therefore, a critical need exists to bring attention to the potential limitations and adverse effects of these therapies to inform and limit misinformation. Study Design and Methods: We describe the extent of the unproven cellular therapy problem through a search of scientific literature and social media coverage. We also describe the regulatory framework that can be used by the practitioner to review and evaluate both proven and unproven cellular therapies. Results: We report on the current state of unproven cellular therapies across the globe. A workflow to facilitate an understanding of the regulatory processes involved in the approval of cellular therapies is provided as well as a list of warnings required by regulatory agencies on various products. It is hoped that this article will serve as a tool kit to educate the practitioner on navigating the field of unproven cellular therapy products. Discussion: Increasing awareness of the issues associated with unproven therapies through education is important to help in reducing misinformation and risks to patients.

Idioma originalEnglish
Páginas (desde-hasta)518-532
Número de páginas15
PublicaciónTransfusion
Volumen62
N.º3
DOI
EstadoPublished - mar 2022
Publicado de forma externa

Huella

Profundice en los temas de investigación de 'How do I: Evaluate the safety and legitimacy of unproven cellular therapies?'. En conjunto forman una huella única.

Citar esto